Biosense Webster – Health Economics & Outcomes Research

Health Economics

Biosense Webster, Inc. expands patient access to our advanced technologies by articulating the clinical and economic value associated with our innovative products through peer-review health economic modelling.

stethoscope

Treatment of Atrial Fibrillation Using Ablation Index- Guided Contact Force Ablation: A Matching-Adjusted Indirect Comparison to Cryoballoon Ablation 

health economics target 1

Objective

Compare the effectiveness of THERMOCOOL SMARTTOUCH® Catheter/THERMOCOOL SMARTTOUCH® SF Catheter with Ablation Index (STAI) on recurrence of atrial arrhythmias 12 months after catheter ablation to that of Arctic Front Advance™ (CB)

health economics notepad 1

Methods

  • Matching Adjusted Indirect Comparison 
  • STAI: IPD from two prospective studies, Solimene et al. 2019 and Hussein et al. 2017. 

  • Three CB studies were identified in a systematic literature review 

health economics graph 1

Results

When age, sex, and LVEF were adjusted, a significant 70% reduction in recurrence rate was associated with STAI when compared to CB (HR 0.30; 95% CI 0.13–0.71). 

Comparative Effectiveness of Catheter Ablation Devices in the Treatment of Atrial Fibrillation: A Network Meta-analysis of Patients in Prospective Studies 

health economics target 2

Objective

Compare the effectiveness of THERMOCOOL SMARTTOUCH® Catheter/THERMOCOOL SMARTTOUCH® SF Catheter with Ablation Index/ SURPOINT™ (STAI) to other available catheters for AF ablation.

health economics notepad 2

Methods

  • Bayesian network meta-analysis 
  • 12 studies (1,722 patients) were identified in a systematic literature review 

health economics graph 2

Results

STAI was associated with were significantly higher freedom from atrial arrhythmias at 12 months

  • 77% greater likelihood than Arctic Front
  • 41% greater likelihood than Arctic Front Advance™
  • 34% greater likelihood than THERMOCOOL™ Catheter
  • 9% greater likelihood than THERMOCOOL SMARTTOUCH® Catheter/THERMOCOOL SMARTTOUCH® SF Catheter alone

Cost Minimization Analysis of Catheter Ablation for Paroxysmal Atrial Fibrillation by Catheter Technology 

health economics target 3

Objective

Evaluate the costs of AF ablation with the THERMOCOOL SMARTTOUCH® Catheter (ST), THERMOCOOL SMARTTOUCH® SF Catheter (SF) and Arctic Front Advance™ Cardiac Cryoablation Catheter (CB).

health economics notepad 3

Methods

  • A decision tree model was developed to compare outcomes of simulated scenarios 

  • Cost outcomes were compared between ablations using ST vs. SF, and ablations using ST vs. CB 

health economics results

Results

  • Expected savings for ST compared to CB was $8,206 (inpatient), $3,859 (outpatient) and $4,494 (hospital mix) 

  • Expected savings for ST compared to SF was $1,763 (inpatient), $1,405 (outpatient) and $1,488 (hospital mix) 

References

The third-party trademarks used herein are the trademarks of the respective owners. 

140148-200513